JP2017501201A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501201A5
JP2017501201A5 JP2016544368A JP2016544368A JP2017501201A5 JP 2017501201 A5 JP2017501201 A5 JP 2017501201A5 JP 2016544368 A JP2016544368 A JP 2016544368A JP 2016544368 A JP2016544368 A JP 2016544368A JP 2017501201 A5 JP2017501201 A5 JP 2017501201A5
Authority
JP
Japan
Prior art keywords
pharmaceutical
parts
pharmaceutical composition
composition according
diluents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501201A (ja
JP6588915B2 (ja
Filing date
Publication date
Priority claimed from GBGB1400034.3A external-priority patent/GB201400034D0/en
Application filed filed Critical
Publication of JP2017501201A publication Critical patent/JP2017501201A/ja
Publication of JP2017501201A5 publication Critical patent/JP2017501201A5/ja
Application granted granted Critical
Publication of JP6588915B2 publication Critical patent/JP6588915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2016544368A 2014-01-02 2015-01-02 Ａｚｄ９２９１を含む医薬組成物 Active JP6588915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1400034.3 2014-01-02
GBGB1400034.3A GB201400034D0 (en) 2014-01-02 2014-01-02 Pharmaceutical Compositions comprising AZD9291
PCT/GB2015/050001 WO2015101791A1 (en) 2014-01-02 2015-01-02 Pharmaceutical compositions comprising azd9291

Publications (3)

Publication Number Publication Date
JP2017501201A JP2017501201A (ja) 2017-01-12
JP2017501201A5 true JP2017501201A5 (enExample) 2018-02-08
JP6588915B2 JP6588915B2 (ja) 2019-10-09

Family

ID=50191689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544368A Active JP6588915B2 (ja) 2014-01-02 2015-01-02 Ａｚｄ９２９１を含む医薬組成物

Country Status (37)

Country Link
US (6) US10183020B2 (enExample)
EP (1) EP3089741B1 (enExample)
JP (1) JP6588915B2 (enExample)
KR (1) KR102336378B1 (enExample)
CN (2) CN105848647B (enExample)
AR (1) AR098989A1 (enExample)
AU (1) AU2015204218B2 (enExample)
CA (1) CA2933403C (enExample)
CL (1) CL2016001609A1 (enExample)
CR (1) CR20160310A (enExample)
CY (1) CY1124848T1 (enExample)
DK (1) DK3089741T3 (enExample)
DO (1) DOP2016000156A (enExample)
EA (1) EA034243B9 (enExample)
ES (1) ES2873226T3 (enExample)
GB (1) GB201400034D0 (enExample)
GT (1) GT201600142A (enExample)
HR (1) HRP20210749T1 (enExample)
HU (1) HUE054344T2 (enExample)
IL (1) IL246186B (enExample)
LT (1) LT3089741T (enExample)
MX (1) MX367358B (enExample)
MY (1) MY183536A (enExample)
NI (1) NI201600098A (enExample)
NZ (1) NZ721298A (enExample)
PE (1) PE20161170A1 (enExample)
PH (1) PH12016501310B1 (enExample)
PL (1) PL3089741T3 (enExample)
PT (1) PT3089741T (enExample)
RS (1) RS61927B1 (enExample)
SG (1) SG11201605339QA (enExample)
SI (1) SI3089741T1 (enExample)
SM (1) SMT202100330T1 (enExample)
TW (1) TWI702953B (enExample)
UY (1) UY35933A (enExample)
WO (1) WO2015101791A1 (enExample)
ZA (1) ZA201605300B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (enExample) 2014-01-24 2018-02-24
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
CN110013468B (zh) * 2018-01-09 2022-02-18 北京福元医药股份有限公司 一种azd9291氘代衍生物药物制剂
WO2019138346A1 (en) * 2018-01-10 2019-07-18 Alembic Pharmaceuticals Limited Pharmaceutical composition of osimertinib
MA51823A (fr) * 2018-02-12 2021-05-19 Astrazeneca Ab Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
PT3758708T (pt) * 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
CN109496150A (zh) * 2018-03-23 2019-03-19 无锡双良生物科技有限公司 一种药物组合物及其制备方法和用途
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
JP2022526159A (ja) 2019-03-29 2022-05-23 アストラゼネカ・アクチエボラーグ 非小細胞肺がんの治療に使用するためのオシメルチニブ
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20230056604A1 (en) 2020-01-20 2023-02-23 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TW202304457A (zh) * 2021-03-22 2023-02-01 瑞典商阿斯特捷利康公司 配製物
CN119278041A (zh) 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
AU2023262556A1 (en) 2022-04-28 2024-12-05 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
JP2025525410A (ja) 2022-06-27 2025-08-05 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮成長因子受容体チロシンキナーゼ阻害剤を伴う組み合わせ
CA3261476A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Combination with HGF Receptor Inhibitors for the Treatment of Cancer
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途
TWI901422B (zh) * 2023-10-31 2025-10-11 大陸商浙江同源康醫藥股份有限公司 一種嘧啶類衍生物的藥物組合物
WO2025162472A1 (en) 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
AU2001248751A1 (en) * 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
CN1326569C (zh) 2002-02-26 2007-07-18 阿斯特拉曾尼卡有限公司 含有水溶性纤维素衍生物的iressa药物制剂
WO2006037763A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
JP5576922B2 (ja) * 2006-04-20 2014-08-20 信越化学工業株式会社 腸溶性固体分散体を含んでなる固形製剤
JP2010533205A (ja) * 2007-07-12 2010-10-21 トラガラ ファーマシューティカルズ，インク． 癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物
EP2696857A1 (en) 2011-04-11 2014-02-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising bosentan
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
DK3686193T3 (da) * 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
EP3181128B1 (en) * 2012-01-13 2023-03-08 XSpray Pharma AB (publ) Nilotinib pharmaceuticalcomposition
WO2013160916A1 (en) 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291

Similar Documents

Publication Publication Date Title
CN105848647B (zh) 包含azd9291的药用组合物
CN109906077B (zh) 依达拉奉与(+)-2-莰醇的舌下用药物组合物
BRPI0908340A2 (pt) composição farmacêutica para fármacos pouco solúveis
AU2015326392B2 (en) Pharmaceutical compositions comprising alpelisib
EP2073791B1 (en) Capecitabine pediatric tablets
JP2012512142A (ja) カペシタビン速崩壊性錠剤
CA3154802A1 (en) Pharmaceutical composition comprising selexipag
ES2674811T3 (es) Composiciones estables de fesoterodina
JP2020203874A (ja) ロキソプロフェン又はその塩とカノコソウとを含有する経口用医薬組成物
JP7366108B2 (ja) ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物
AU2011253775B2 (en) Compositions and Methods for Increasing Blood Platelet Levels in Humans
US20170128482A1 (en) Modified release pharmaceutical compositions of sofosbuvir and ribavirin
JP2020169152A (ja) ロキソプロフェン又はその塩とボタンピとを含有する経口医薬組成物
JP2018076312A (ja) アセトアミノフェン、イソプロピルアンチピリン及びショウガ由来成分を含有する医薬組成物
EP2959888A1 (en) A novel pharmaceutical composition of sofosbuvir and ribavirin
JP2007284394A (ja) 被覆固形製剤
TR201516738A2 (tr) Oral terapöti̇k formülasyonlar
WO2013137441A1 (ja) 経口医薬組成物